IMPI: Prednisolone for tuberculous pericarditis

Tuberculous pericarditis is associated with high morbidity and mortality. This study included 1400 patients with definite or probable tuberculous pericarditis to receive prednisolone or placebo for 6 weeks. Two-thirds of patients had concomitant HIV infection. The primary end point was a composite of death, tamponade, or constrictive pericarditis. No significant differences between those who received corticosteroids versus those receiving placebo (23, 8% versus 24, 5%; p=0.66) were observed. 

5_bongani_mayosi
Bongani M. Mayosi
2014-09-02

Original title: IMPI Steroid Study: A Trial of Adjunctive Prednisolone in Tuberculous Pericarditis.

More articles by this author

IBIS 4: intensive treatment with statins after ST-segment elevation myocardial infarction

Statins may help stabilize the atherosclerotic plaque in acute myocardial infarction. 103 patients who underwent primary angioplasty followed by coronary intravascular ultrasound (IVUS) in...

AMIO-CAT: Amiodarone after ablation of atrial fibrillation

Early recurrence of atrial fibrillation after ablation is an experience that discourages patients. The aim of this study was to analyze the overall effectiveness...

X-Vert: Rivaroxaban in patients with atrial fibrillation undergoing elective cardioversion

This study included 1504 patients with atrial fibrillation and indication for elective electrical cardioversion who were randomized to rivaroxaban (n = 1002) versus Marevan...

STICS: perioperative statins to prevent atrial fibrillation

The aim of this study was to test whether perioperative treatment with rosuvastatin 20 mg could prevent the incidence of postoperative atrial fibrillation and...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | ALL-RISE Trial: Coronary Physiological Assessment Using FFRangio

Coronary physiological assessment using pressure-wire techniques (FFR/iFR) carries a Class IA recommendation in ACC/AHA guidelines; however, its use remains limited due to factors such...

ACC 2026 | Protect The Head-To-Head Trial: Randomized Comparison Between Emboliner and Sentinel During TAVI

Ischemic stroke remains one of the most feared complications of TAVI, with a relatively low but persistent incidence of 2–4%, without significant reduction over...

ACC 2026 | PRO-TAVI Trial: Deferring Coronary Angioplasty in Patients Undergoing TAVI

Coronary artery disease is common in patients with severe aortic stenosis undergoing TAVI. Current guidelines recommend considering revascularization in significant coronary lesions, particularly in...